402 related articles for article (PubMed ID: 18375236)
1. Niacin use and cutaneous flushing: mechanisms and strategies for prevention.
Davidson MH
Am J Cardiol; 2008 Apr; 101(8A):14B-19B. PubMed ID: 18375236
[TBL] [Abstract][Full Text] [Related]
2. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
[TBL] [Abstract][Full Text] [Related]
3. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
Yiu KH; Cheung BM; Tse HF
Expert Opin Investig Drugs; 2010 Mar; 19(3):437-49. PubMed ID: 20141348
[TBL] [Abstract][Full Text] [Related]
4. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
[TBL] [Abstract][Full Text] [Related]
5. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment.
Oberwittler H; Baccara-Dinet M
Int J Clin Pract; 2006 Jun; 60(6):707-15. PubMed ID: 16805757
[TBL] [Abstract][Full Text] [Related]
6. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
[TBL] [Abstract][Full Text] [Related]
7. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
[TBL] [Abstract][Full Text] [Related]
8. A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
Jacobson TA
Mayo Clin Proc; 2010 Apr; 85(4):365-79. PubMed ID: 20360295
[TBL] [Abstract][Full Text] [Related]
9. Safety of niacin and simvastatin combination therapy.
Bays H
Am J Cardiol; 2008 Apr; 101(8A):3B-8B. PubMed ID: 18375239
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacology of niacin or nicotinic acid].
Santos RD
Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():17-9. PubMed ID: 16400392
[TBL] [Abstract][Full Text] [Related]
11. Ask the doctor. I tried taking niacin to increase my HDL but didn't like the flushing it caused. A friend told me about no-flush niacin, which works like a charm. Why not tell your readers about it?
Lee T
Harv Heart Lett; 2010 Mar; 20(7):8. PubMed ID: 20586132
[No Abstract] [Full Text] [Related]
12. Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview.
Kamal-Bahl S; Watson DJ; Ambegaonkar BM
Clin Ther; 2009 Jan; 31(1):130-40. PubMed ID: 19243714
[TBL] [Abstract][Full Text] [Related]
13. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
Bays HE; Ballantyne C
Curr Opin Lipidol; 2009 Dec; 20(6):467-76. PubMed ID: 19779335
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of extended-release niacin with laropiprant.
Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
[TBL] [Abstract][Full Text] [Related]
15. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.
Olsson AG
Expert Opin Pharmacother; 2010 Jul; 11(10):1715-26. PubMed ID: 20518616
[TBL] [Abstract][Full Text] [Related]
16. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
[TBL] [Abstract][Full Text] [Related]
17. The mechanism and mitigation of niacin-induced flushing.
Kamanna VS; Ganji SH; Kashyap ML
Int J Clin Pract; 2009 Sep; 63(9):1369-77. PubMed ID: 19691622
[TBL] [Abstract][Full Text] [Related]
18. The safety of niacin in the US Food and Drug Administration adverse event reporting database.
Alsheikh-Ali AA; Karas RH
Am J Cardiol; 2008 Apr; 101(8A):9B-13B. PubMed ID: 18375244
[TBL] [Abstract][Full Text] [Related]
19. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
[TBL] [Abstract][Full Text] [Related]
20. The effect of aspirin on niacin-induced cutaneous reactions.
Whelan AM; Price SO; Fowler SF; Hainer BL
J Fam Pract; 1992 Feb; 34(2):165-8. PubMed ID: 1737967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
